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Background & Aims: Genetic factors associated with non- alcoholic fatty liver disease (NAFLD) remain incompletely  un- derstood. To date, most genome-wide association studies (GWASs) have adopted radiologically assessed hepatic triglycer- ide content as the reference phenotype and so cannot address steatohepatitis or ﬁbrosis. We describe a GWAS encompassing the full spectrum of  histologically characterised  NAFLD. Methods: The GWAS involved 1,483 European NAFLD cases and 17,781 genetically matched controls. A replication cohort of 559 NAFLD cases and 945 controls was genotyped to conﬁrm signals showing genome-wide or close to genome-wide signiﬁcance.

Results:   Case-control   analysis   identiﬁed   signals   showing   p
values   <−5  ×   10−8   at   4   locations   (chromosome   [chr]   2   GCKR/ C2ORF16; chr4 HSD17B13; chr19 TM6SF2; chr22 PNPLA3) together with 2 other signals with p <1 × 10−7 (chr1 near LEPR and chr8
near IDO2/TC1). Case-only analysis of quantitative traits showed that the PNPLA3 signal (rs738409) had genome-wide signiﬁcance for steatosis, ﬁbrosis and NAFLD activity score and a new signal (PYGO1 rs62021874) had close to genome-wide signiﬁcance for steatosis (p = 8.2 × 10−8). Subgroup case-control analysis for NASH conﬁrmed the PNPLA3 signal. The chr1 LEPR single nucleotide polymorphism also showed genome-wide signiﬁ- cance   for   this   phenotype.   Considering   the   subgroup   with
advanced  ﬁbrosis  (>−F3),  the  signals  on  chr2,  chr19  and  chr22 maintained  their  genome-wide  signiﬁcance.  Except  for  GCKR/
C2ORF16, the genome-wide signiﬁcance signals were replicated. Conclusions: This study conﬁrms PNPLA3 as a risk factor for the full histological spectrum of NAFLD at genome-wide signiﬁcance levels, with important contributions from TM6SF2 and HSD17B13. PYGO1 is a novel steatosis modiﬁer, suggesting that Wnt sig- nalling pathways may be relevant in NAFLD pathogenesis.

















result in cirrhosis. To understand who is at risk of developing this disease and suffering liver damage, we undertook a genetic study to compare the genetic proﬁles of people suffering from  fatty liver disease with genetic proﬁles seen in the general population. We found that particular sequences in 4 different areas of the human genome were seen at different frequencies in the fatty liver disease cases. These sequences may help predict an indi- vidual's risk of developing advanced disease. Some genes where these sequences are located may also be good targets for future drug treatments.
© 2020 European Association for the Study of the Liver. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ (​http:​/​​/​creativecommons.org​/​licenses​/​by-nc-nd​/​4.0​/​​)).

Introduction
Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of progressive liver disease characterised by increased hepatic triglyceride content (HTGC) in the absence of excess alcohol consumption.NAFLD encompasses steatosis (non-alcoholic fatty liver [NAFL]), steatohepatitis (non-alcoholic steatohepatitis [NASH]), ﬁbrosis and ultimately cirrhosis. It is strongly associated with features of the metabolic syndrome (obesity, type 2 dia- betes mellitus [T2DM] and dyslipidaemia). Although common, affecting approximately 25% of the global adult population, only a minority of patients with NAFL develop NASH, progress to signiﬁcant ﬁbrosis or experience associated morbidity., NAFLD is best considered a complex trait where disease phenotype re- sults from environmental exposures acting on a susceptible polygenic background comprising multiple independent modiﬁers.
Genome-wide association studies (GWASs) have contributed greatly to our understanding of the genetic contribution to NAFLD pathogenesis and variability of prognosis. Amongst the loci identiﬁed, the non-synonymous single nucleotide poly- morphism (SNP) in PNPLA3 (phospholipase  domain-containing 3) (rs738409),, and more recently, a non-synonymous SNP in TM6SF2 (transmembrane 6 superfamily member 2) (rs58542926), originally ascribed to the neighbouring NCAN gene, have been associated with  1H-MRS  quantiﬁed  HTGC. Both genetic associations have  been  replicated  in  further studies where they have been associated not only with steatosis, but also with clinically relevant factors including grade of stea- tohepatitis and stage of hepatic ﬁbrosis/cirrhosis, and, in the case of PNPLA3, with the development of NAFLD-related hepa- tocellular carcinoma., A number of other associations, with LYPLAL1, GCKR, and PPP1R3B, have been reported by GWAS comprising relatively few histologically characterised cases and are currently less robustly replicated., A recent study using exome sequencingconﬁrmed a previously reported association of raised alanine aminotransferase (ALT) with a HSD17B13 SNP (rs6834314) in a general patient population and then demon- strated that this polymorphism was associated with NAFLD. Two further studies broadly conﬁrmed this association.,
To date, most adequately powered GWASs relevant to NAFLD have addressed either radiologically determined HTGC,, or clinical biochemistry parameters such as ALT., They have therefore been unable to address the more clinically relevant phenotypes of steatohepatitis grade or ﬁbrosis stage (reviewed). One GWAS has assessed a large number of histologically char- acterised patients, reporting associations with both PNPLA3 and with chromosome 19 close to TM6SF2.These patients, however,





For the main GWAS study, patients were recruited from clinics at several leading European tertiary liver centres (see supplementary methods). Additional cases for replication were recruited at Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. The study had the necessary ethical ap- provals from the relevant national/institutional review boards (see supplementary methods) and all participants provided informed consent. All cases were unrelated patients that had undergone a liver biopsy as part of the  routine  diagnostic workup for presumed NAFLD having originally been identiﬁed due to abnormal biochemical tests (ALT and/or gamma- glutamyltransferase) and/or an ultrasonographically detected bright liver, associated with features of the metabolic syndrome; or having abnormal biochemical tests (ALT and/or gamma- glutamyltransferase) and macroscopic appearances of a stea- totic liver at the time of bariatric surgery. Full details of inclusion/ exclusion criteria are provided in the supplementary methods.

Controls
We used general population samples with existing genome-wide genotype data as study controls. For the GWAS, we selected European ancestry controls (n = 17,781) from multiple sources as described in the supplementary methods. To replicate GWAS associations, we used an Italian control cohort (n = 945) con- sisting of controls described previously with some newly collected individuals. Any that were found to match the Hyper- genes controls already used in our discovery GWAS were excluded.

Histology















(B0-2); degree of lobular inﬂammation (I0-3); severity of NASH activity (calculated as ‘disease activity’ = hepatocyte ballooning (B0-2) + lobular inﬂammation (I0-3) and also an overall NAFLD activity score ‘NAS’ combining all 3 parameters (NAS0-8)); and stage of ﬁbrosis (F0-4).

Genotyping
DNA was prepared from blood samples collected with EDTA as described previously. GWAS genotyping was carried out in 2 phases. For phase I, genotyping was performed initially using the Illumina OmniExpress BeadChip by Edinburgh Clinical Research Centre. To obtain data for additional exomic SNPs, further gen- otyping of these samples was performed using the Illumina HumanCoreExome BeadChip (Aros, Denmark). Genome-wide genotyping of the phase II cases was performed using the Illu- mina OmniExpressExome BeadChip by the Edinburgh Clinical Research Centre. A total of 721,078 markers shared across the batches passed quality control (see supplementary  methods). SNP imputation was performed as described in detail in the supplementary methods.
The top associated SNPs were further conﬁrmed in replication cases using TaqMan® SNP genotyping assays (ThermoFisher Scientiﬁc, Waltham, MA) in accordance with the manufacturer's recommendations. If an assay could not be designed for the SNP showing the strongest signal for the region, a suitable proxy SNP was chosen (https://ldlink.nci.nih.gov/?tab = home (​https:​/​​/​ldlink.nci.nih.gov​/​?tab%20=%20home​)).

RNA sequencing and in vitro studies
RNA sequencing
RNA sequencing data on samples from 206 liver biopsies from patients with NAFLD, as described elsewhere (Govaere et al., submitted), was used to further investigate the functional sig- niﬁcance of HSD17B13 variants.

Bioluminescent retinol dehydrogenase assays for HSD17B13 Retinol (75 lM; Sigma-Aldrich, St. Louis, Missouri, USA) was incubated with recombinant HSD17B13 (TP313132; Origene, Maryland, USA) for 1 h at room temperature in the presence of
0.5 mM NAD in 200 mM Tris-HCl, pH7.5. As a control, the known HSD17B13 substrate b-estradiol (75 lM) was incubated in par- allel assays. NADH production was measured by Bioluminescent NAD/NADH-GloTM Assay (Promega, Wisconsin, USA) according to manufacturer's guidelines.

Statistical analysis
We used principal component analysis (PCA) of the  genome- wide genotype data to investigate the ancestry of the cases and controls; this showed the expected north/south variation commonly seen across Europe but, importantly, suggested adequate matching between cases and controls (Fig S1A and Fig S1B). Case/control analysis and quantitative trait analysis of GWAS data was performed as described in detail in the supplementary methods, using a linear mixed modelling
p values by univariate analysis and multiple logistic regression using PLINK.

Results
Clinical characteristics of the cases
Clinical details of  the NAFLD cases included in the main GWAS are summarised in . The replication cohort details are shown in Table S1. All cases in both cohorts were of white Eu- ropean ethnicity. The percentage with advanced  ﬁbrosis (stage F3 or F4) was similar in both cohorts (p >0.05) but other pa- rameters including age, BMI, T2DM, sex and incidence of NASH were different.

Overall NAFLD case-control analysis
The overall NAFLD case-control analysis is presented as a Man- hattan plot (). PCA scattergrams for cases and controls are shown in  Fig S1  and the  QQ plot of  the association  results  in Fig S2. As summarised in , 4 different regions (on

Table 1. Characteristics of the cohort (n = 1,483). Patient demographic and clinical characteristics

Sex (% female)	47.30%





































genomic control inﬂation factors (k) (see Results)  indicated that this adjustment adequately corrected for any population differences.




NAS, non-alcoholic fatty liver disease activity score; NASH, non-alcoholic steatohe- patitis; T2DM, type 2 diabetes mellitus.












performed. This analysis gave broadly similar ﬁndings to those
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Quantitative trait analysis of NAFLD phenotypes






Fig. 1. Manhattan plot from imputed GWAS case-control analysis. Included 1,483 NAFLD cases and 17,781 controls. Threshold for genome-wide signiﬁ- cance was taken to be 5 × 10−8. The ﬁrst 5 principal components were included as covariates. Genome-wide signiﬁcant signals are indicated by blue arrows with those showing p in the range 1 × 10−7 to 5 × 10−8 shown by grey arrows. GWAS, genome-wide association study; NAFLD, non-alcoholic fatty liver dis- ease. (This ﬁgure appears in color on the web.)

chromosomes 2, 4, 19 and 22) passed conventional genome-wide signiﬁcance (p <5 × 10−8) with 2 other regions (on chromosomes 1 and 8) showing p values <1 × 10−7 (for LocusZoom plots see Fig S3). Data presented in  were obtained from imputation analysis. Primary case-control analysis without imputation showed similar signals in chromosomes 2, 4, 19 and 22 only but no additional signals at p <1 × 10−7 (Fig. S4 and Table S2). Correction of the imputed data for sex in addition to the ﬁrst 5 principal components used in the main analyses did not result in large changes in p value (Table S3). Together, these results point to PNPLA3, TM6SF2, HSD17B13 and the GCKR/C2ORF16 region being the major risk factors for disease susceptibility with borderline signals for chromosome 1 near LEPR and for chro- mosome 8 adjacent to IDO2 and TC1(C8orf4). In view of the well- established strong association of PNPLA3 rs738409 with NAFLD, additional analysis using a model conditioning on this SNP was
when ballooning or inﬂammation were considered as individual traits (Fig. S8). The effect of correction of the imputed data for clinical covariates was also assessed for each trait (Table S5), giving results very similar to those obtained originally.
To further assess the relevance of genotype to particular NAFLD phenotypes, the contribution to NAFLD progression of the 4 major genetic risk factors identiﬁed in the case-control GWAS was assessed by calculating a combined genetic risk score based on summing the allele count (with no weighting by effect size) for PNPLA3 rs738409, TM6SF2 rs58542926, GCKR rs1260326 and
HSD17B13 rs9992651 and relating the resulting score to grade of steatosis, NAS and ﬁbrosis stage (Fig. S9). Trend tests by linear regression showed that there was a statistically signiﬁcant rela- tionship between the value of the semi-quantitative steatosis/ NAS/ﬁbrosis scores and the value of the genetic risk score for all 3 phenotypes, with the most signiﬁcant relationship (p = 4.68 × 10−13) detected for ﬁbrosis stage (Fig S9). Those with a risk score of 2 (n = 216) had a mean ﬁbrosis score of 1.27 (SE 0.08) compared with 1.94 (SE 0.09) for a risk score of 5 (n = 260).

Additional subgroup case-control analysis





Table 2.  Summary of top ﬁndings in the NAFLD case-control analysis.













7,412,561 imputed SNPs included; total number of cases and controls = 19,264. ORs were obtained from logistic regression in PLINK and conﬁdence intervals were calculated from back-transformation of FaST-LMM p-values and PLINK ORs.
OR, odds ratio; SNP, single nucleotide polymorphism.
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and ﬁbrosis stage F3 and F4 only (n = 386). The ﬁndings for both phenotypes are summarised in  and  (for QQ and LocusZoom plots see Fig. S10 and S11). For NASH, signals showing p values of <5 × 10−8 were detected for chromosome 1 (LEPR) and chromosome 22 (PNPLA3) (). For LEPR rs12077210, the p value of 4.4 × 10−9 was lower for NASH than for NAFLD overall (). A second novel chromosome 1 signal (rs80084600) with p = 7.1 × 10−8 located in an intergenic region downstream of phospholipase A2 group IVA (PLA2G4A) was also detected. The SNPs in chromosomes 2, 4 and 19 that were sig- niﬁcant in the main case-control analysis showed p values in the region of 2 × 10−7 so came close to signiﬁcance for NASH. For ﬁbrosis stages F3 and F4, chromosome 2, 19 and 22 signals showing p values of <5 × 10−8 were detected but the signals from the main case-control analysis detected previously for chromo- somes 1, 8 and 4 showed p values >1 × 10−7. For HSD17B13 rs9992651 (chromosome 4), the p value was 1.16 × 10−5.

Replication of GWAS signals and investigation of additional possible NAFLD risk factors
A replication cohort of 559 Italian NAFLD cases was assembled from a different centre to the discovery cohort. Allele frequencies for selected SNPs in these cases were compared with those for Italian controls. Findings for 8 separate loci giving signals with
p <1 × 10−7 in either the main GWAS or the quantitative trait studies are summarised in . The PNPLA3, TM6SF2 and HSD17B13 signals seen in the main GWAS replicated (p <0.05) but we found only borderline effects or no signiﬁcance for 4 other loci. However, the PYGO1 signal, which was associated with steatosis by quantitative trait analysis, showed a signiﬁcant as- sociation in the analysis in the same protective direction as observed for steatosis. The GCKR/C2Orf16 signal did not replicate either in the main replication cohort () or in a subgroup of replication cases (n = 134) with ﬁbrosis stage 3 or 4. Due to the relatively low number of NASH cases in the replication cohort, we did not seek to replicate the novel rs80084600 signal seen for this phenotype. Multiple logistic regression analysis with adjustment for PNPLA3 rs738409 and TM6SF2 rs58542926 () generated similar ﬁndings to the univariate analysis, apart from small de- creases in p values for the HSD17B13 and PYGO1 signals.













Table 3.  Summary of top ﬁndings in quantitative trait analysis.
SNP	Chromosome	A1	Gene	Phenotype	n	p value (no clinical covariates)	Beta (95% CI)
rs738409	22	G	PNPLA3	Steatosis	1,469	2.37E−09	0.183 (0.123–0.243)
rs62021874	15	T	PYGO1	Steatosis	1,469	8.16E−08	−0.303 (−0.414 to −0.192)
rs11858624	15	T	PYGO1	Steatosis	1,469	1.64E−07	−0.295 (−0.406 to −0.185)
rs738409	22	G	PNPLA3	Fibrosis	1,481	7.58E−11	0.318 (0.222–0.414)
rs738409	22	G	PNPLA3	NAS	1,467	8.78E−09	0.364 (0.240–0.488)
Results for 7,900,223 imputed SNPs. First 5 principal components were included as covariates. ORs were obtained from logistic regression in PLINK and conﬁdence intervals were calculated from back-transformation of FaST-LMM p-values and PLINK ORs.
SNP, single nucleotide polymorphism.
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signals is limited. The relationship of rs9992651 and rs72613567 in HSD17B13 with gene expression was evaluated by sequencing RNA samples from liver biopsies. Three different HSD17B13 transcripts were detected (Fig. S12), including a full-length transcript with all 7 exons, a variant with exon 2 deleted and a variant without exon 6. Based on genotype for rs9992651 from the RNA sequencing data, the variant without exon 6 was generally not detectable in homozygotes for the  reference  G allele but was expressed at a higher level in homozygotes for the minor A allele and also heterozygotes. The ability of recombinant HSD17B13 to oxidise retinol was also conﬁrmed (Fig. S13).
Other loci showing associations in the case-control studies including rs12077210 in LEPR (intronic), rs139648192 on chro- mosome 8 and rs80084600 on chromosome 1 could not be investigated  by  RNA  sequencing  due  to  their  locations.  The
















missense variant (P299H). Analysis with data obtained  from GTEx (https://gtexportal.org/home/ (​https:​/​​/​gtexportal.org​/​home​/​​)) indicated no difference in RNA expression between rs11858624 homozygous wild-types and heterozygotes in liver tissue (Fig. S14).

Discussion
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Fig.  3.   Manhattan plots from imputed GWAS case-control analysis  of NASH and severe ﬁbrosis (F3/F4). Threshold for genome-wide  signiﬁcance  was taken to be 5 × 10−8. The ﬁrst 5 principal components were included as covariates. Panel A. NASH analysis. 836 cases and 17,781 controls. Panel B. F3/ F4 analysis. 386 cases and 17,781 controls. Genome-wide signiﬁcant signals are indicated by blue arrows with those showing p in the range 1 × 10−7 to 5 × 10−8 shown by grey arrows. GWAS, genome-wide association study; NASH, non- alcoholic steatohepatitis. (This ﬁgure appears in color on the web.)

EQTL analysis and studies on expression of GWAS signals in liver biopsies from different NAFLD stages
While the signals seen for NAFLD relating to PNPLA3, TM6SF2 and GCKR are already well-established risk factors for this disease from population studies, and studies on functional signiﬁ- cance, evidence for functional signiﬁcance for the other
established signals in PNPLA3, TM6SF2 and GCKR, together with the more recently reported HSD17B13 signal. The ﬁndings for GCKR are in line with several candidate gene studies on NAFLD however, this is the ﬁrst GWAS study reporting this 4 gene combination as NAFLD risk modiﬁers.












Table 4.  Summary of top ﬁndings from case-control analysis for NAFLD cases with NASH or with ﬁbrosis scores F3 and F4 only.














N = 18,167 (Cases = 386, Controls = 17,781), covariate model includes ﬁrst 5 principal components. ORs were obtained from logistic regression in PLINK and conﬁdence intervals were calculated from back-transformation of FaST-LMM p-values and PLINK ORs.






























Signiﬁcance of ﬁndings was assessed by calculation of odds ratios, 95% conﬁdence intervals and p values by univariate analysis (chi-square test) and multiple logistic regression using PLINK.





showing a similar splicing pattern  with  the  SNPs  rs6834314 and rs72613567 but differing from that described in the original report. Consistent with that recent study, we also show the HSD17B13 gene product possesses retinol dehydro- genase activity. Retinol metabolism is a complex multistep process involving a number of different enzymes. While it remains unclear whether loss of HSD17B13 retinol dehydro- genase activity can  explain the  protective  effect of  the  variant, it is likely that enzyme activity  in  the  reverse  direction involving retinal reduction to retinol could also  be  impaired since these enzymes operate in both oxidising and reducing directions. Thus, increased levels of retinal and the  biologi- cally active retinoic acid isomers could occur in those carrying HSD17B13 variants. This effect might protect against NAFLD development, in line with recent evidence that 13-cis and all- trans retinoic acid are found at signiﬁcantly decreased levels in human livers with NAFLD. A clear trend towards a protective effect against advanced hepatic ﬁbrosis was observed, although this did not reach genome-wide signiﬁcance levels (p value approx. 10−5). Given that the strength of association with NASH was stronger (p values approx. 2 × 10−7), it may be that the protective effect of HSD17B13 is more  relevant  to development of steatohepatitis than progression of ﬁbrosis.
The GCKR signal in both the main GWAS and advanced ﬁbrosis-only analysis identiﬁed rs1260326 as the most signiﬁ- cant SNP within this region, with T-variant carriage increasing
NAFLD risk. This common missense variant has been studied widely both as a risk factor for T2DM and for NAFLD. An up- stream SNP, rs780094, in strong linkage disequilibrium with rs1260326, has also been shown to be a NAFLD risk factor in candidate gene studies. The relationship between both  SNPs and susceptibility to NAFLD and T2DM is complex. Rs1260326 is well established to have a protective effect against T2DM, probably due to the GCKR variant showing weaker interaction with glucokinase compared with the wild-type.This promotes hepatic glucose metabolism, decreasing plasma glucose levels, and is associated with an increased risk of NAFLD. The un- derlying mechanism is unclear but rs1260326 is associated with higher levels of circulating lactate, presumably  due  to increased glucose metabolism via glycolysis. The inability to replicate the GCKR association was slightly surprising but may reﬂect the overall lower severity of NAFLD in the replication cohort. There are a relatively large number of reports of a sig- niﬁcant increased risk for GCKR variants in NAFLD generally, especially for paediatric cases.,,
















including increased adiposity and impaired glucose tolerance in mice lacking this protein.
Signals on chromosomes 1 and 8 were detected in the case- control analysis, however these just failed  to  meet  genome- wide signiﬁcance and  did  not  replicate.  The  chromosome  1 SNP was genome-wide signiﬁcant in the NASH-only case-control analysis and lies in the region encoding LEPROT and LEPR; both genes share the same promoter and ﬁrst 2 exons but encode separate proteins. This association is notable given that db/db mice, carrying a spontaneous loss of function mutation in the OB-Rb leptin receptor, have been widely used to model NAFLD. There are also some previous reports from candidate gene studies that LEPR variants are risk factors for NAFLD but the current variant lies considerably upstream of these previously studied variants., The signal on chromosome 8 relates to an area between IDO2 and TC1. Of potential relevance to NAFLD, both genes have roles in modulating inﬂammation with IDO2 inducible by lipopolysaccharide and contributing to immune function while TC1 modulates NF-jB signalling. Further investigation of these variants is needed. The subgroup analysis on NASH grade showed a second novel chromosome 1 signal separate from LEPR. The p value for NASH, though not genome- wide signiﬁcant at 7 × 10−8, was considerably lower than that seen for this variant in the main case-control study (0.0049). The variant is in an intergenic region but is downstream of PLA2G4A, which shows elevated expression in adipose tissue in obesity and may contribute to T2DM susceptibility.
The most signiﬁcant associations in this study were obtained for NAFLD in the binary case-control design. The quantitative trait analyses has shown a clear association for PNPLA3 rs738409 with steatosis, NAS score and ﬁbrosis, which is generally in line with previous reports in NAFLD and alcohol-related liver dis- ease. However, there were no signiﬁcant associations of any genotype with disease activity when considered separately from steatosis. The failure to see more speciﬁc associations for TM6SF2 and HSD17B13 with other histological traits similar to those re- ported previously in candidate gene studies may reﬂect the complex nature of the histological disease phenotype,and also limited statistical power. In contrast to quantiﬁcation of HTGC by imaging techniques, which provides a highly reproducible quantitative measure of a single biochemical entity, the histo- logical scoring systems used to evaluate steatohepatitis and ﬁbrosis provide only non-linear, semi-quantitative or categorical assessments of disease and are subject to intra- and inter- observer variation.  Indeed,  clear  diagnostic  consensus regarding the presence or absence of steatohepatitis among pa- thologists is not always feasible.,, Thus, the conduct of a histology-based GWAS, whilst addressing the most clinically relevant phenotypic characteristics, is technically more chal- lenging. We have addressed this challenge by using expert liver pathologists to provide histological diagnosis and scoring. The reduced statistical power due to the limited number of cases in particular histological categories, may limit the number of vari- ants that attain the genome-wide signiﬁcance threshold to only the most strongly associated, such as the PNPLA3 variant. Despite these limitations, disease severity was correlated with genetic risk score based on the most signiﬁcant case-control GWAS sig- nals, statistically signiﬁcant relationships for association of the risk score with increasing degree of steatosis, grade of steato- hepatitis and ﬁbrosis stage were found, which suggests that a  risk score approach may be of value prognostically although further studies on this are needed.
Despite a fairly extensive supporting literature, we and others have not found MBOAT7 to be a risk factor for NAFLD. Notably, no NAFLD focussed GWAS to date has reported a sig- niﬁcant association with MBOAT7. Other signals for NAFLD re- ported by others previously including in PPP1R3B, AAT and interferon lambda 4 also failed to show genome-wide signiﬁ- cance in the case-control analysis. This is not surprising in the case of AAT as patients known to have this condition were spe- ciﬁcally excluded from the cohort, limiting the minor allele fre- quency substantially. However, the gene MARC1, where a non- synonymous variant has been reported to protect against  both “all cause” cirrhosis and fatty liver disease, showed a similar protective effect against NAFLD with a low p value, though this did not attain genome-wide signiﬁcance. This gene encodes the mitochondrial amidoxime-reducing component enzyme which can reduce trimethylamine N-oxide (TMAO) generated by oxidation of trimethylamine. Elevated plasma TMAO has been suggested to be a risk factor for cardiovascular disease and T2DM so could also be relevant to NAFLD.
There are several limitations to our study. NAFLD is  a common phenotype in the general population, affecting up  to 25% of individuals in Europe.Our population controls cannot therefore be considered to be entirely free of NAFLD and there is no way of investigating  this  further.  Our  use  of  large numbers of controls with genetic matching helps mitigate  the risk that this will lead to an underestimate of genuine genetic risk factors but does not eliminate it entirely. We  undertook some “case only” studies, which included a small group  of patients with biochemical evidence of  NAFLD  but  liver  bi- opsies showing steatosis  below  the  normal  disease  deﬁnition, to further mitigate this. It is  generally  accepted  that  histo- logical interpretation of liver biopsies is subject to some inter- observer variation, even amongst experienced hepatopathol- ogists., This is therefore inherent to a histopathological phenotype. However, all data used in the  analysis  were generated by highly experienced liver pathologists based in tertiary centres and, to further mitigate against this issue, the majority of liver biopsies were scored by a member of the project's  central  pathology  team.  Finally,  our  replication cohort was not perfectly matched with our discovery cohort in terms of disease severity and factors such as  sex,  T2DM  and BMI. This is due, at least in part, to this being  from  a  single centre from Southern Europe where NAFLD risk factors such as diet may be different to those further north in the continent, resulting in lower obesity rates  within  the  NAFLD  popula- tion. We were unfortunately not able to identify  another suitable European replication  cohort  involving  patients  who had undergone liver biopsy following referral to a hepatology clinic.
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Age (years) (mean ± SD)	50.1 ± 13.0
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nents as  covariates  to  adjust  for any  population  stratiﬁcation.	1	350 (23.6)
Examination  of   the   resulting   genome-wide   QQ   plots   and	2	312 (21.0)
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